270 related articles for article (PubMed ID: 20445285)
21. [Bone disease related to rheumatoid arthritis].
Tanaka S
Nihon Rinsho; 2006 Sep; 64(9):1712-7. PubMed ID: 16972685
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
[TBL] [Abstract][Full Text] [Related]
23. Denosumab and bisphosphonates: different mechanisms of action and effects.
Baron R; Ferrari S; Russell RG
Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
[TBL] [Abstract][Full Text] [Related]
24. [Inflammatory cytokines for osteoclastogenesis].
Tanaka Y
Nihon Rinsho; 2005 Sep; 63(9):1535-40. PubMed ID: 16164208
[TBL] [Abstract][Full Text] [Related]
25. [Secondary osteoporosis. Bone metabolic disorder in Rheumatoid arthritis.].
Nakano K; Okada Y; Tanaka Y
Clin Calcium; 2018; 28(12):1599-1603. PubMed ID: 30487323
[TBL] [Abstract][Full Text] [Related]
26. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
Nakayamada S; Tanaka Y
Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
[TBL] [Abstract][Full Text] [Related]
27. [Recent progress in the treatment of rheumatoid arthritis].
Tanaka Y
Clin Calcium; 2012 Feb; 22(2):169-78. PubMed ID: 22298069
[TBL] [Abstract][Full Text] [Related]
28. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
29. [The impact of controlling bone remodeling in rheumatoid arthritis.].
Ebina K
Clin Calcium; 2017; 27(12):1739-1744. PubMed ID: 29179168
[TBL] [Abstract][Full Text] [Related]
30. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
31. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
32. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
Okada Y; Nawata M; Tanaka Y
Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
[TBL] [Abstract][Full Text] [Related]
33. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
[TBL] [Abstract][Full Text] [Related]
34. [RANKL as a target molecule for treatment of joint destruction].
Tanaka S
Clin Calcium; 2007 Apr; 17(4):586-92. PubMed ID: 17404489
[TBL] [Abstract][Full Text] [Related]
35. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
Scharla SH; Schacht E; Lempert UG
J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
[TBL] [Abstract][Full Text] [Related]
36. [Biologic agents for the treatment of rheumatic diseases].
Tanaka Y
Clin Calcium; 2014 Jun; 24(6):911-7. PubMed ID: 24870843
[TBL] [Abstract][Full Text] [Related]
37. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
38. [Management of osteoporosis associated with rheumatoid arthritis and glucocorticoid-induced osteoporosis].
Suzuki Y; Wakabayashi T
Clin Calcium; 2015 Dec; 25(12):1825-34. PubMed ID: 26608858
[TBL] [Abstract][Full Text] [Related]
39. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
40. [Osteoporosis in RA: pathophysiology and treatment].
Ito Y; Inoue D; Matsumoto T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():463-7. PubMed ID: 15799400
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
